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New molecular insights into the mechanisms of cholestasisq
Martin Wagner, Gernot Zollner, Michael Trauner*
Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal
Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, AustriaRecent progress in basic research has enhanced our understanding of the molecular mechanisms of normal bile secretion
and their alterations in cholestasis. Genetic transporter variants contribute to an entire spectrum of cholestatic liver dis-
eases and can cause hereditary cholestatic syndromes or determine susceptibility and disease progression in acquired chole-
static disorders. Cholestasis is associated with complex transcriptional and post-transcriptional alterations of
hepatobiliary transporters and enzymes participating in bile formation. Ligand-activated nuclear receptors for bile acids
and other biliary compounds play a key role in the regulation of genes required for bile formation. Pharmacological inter-
ventions in cholestasis may aim at modulating such novel regulatory pathways. This review will summarize the principles of
molecular alterations in cholestasis and will give an overview of potential clinical implications.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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The hallmark of cholestasis is an impairment of bile
secretion and ﬂow followed by a lack of bile in the intes-
tine and accumulation of potentially toxic cholephiles in
the liver and the systemic circulation [1]. Normal bile0168-8278/$36.00  2009 European Association for the Study of the Liver.
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Abbreviations: ABC, ATP-binding cassette; BSEP, bile salt export
pump; BRIC, benign recurrent intrahepatic cholestasis; CAR (NR1I3),
constitutive androstane receptor; CBDL, common bile duct ligation;
CYP, cytochrome p450; FXR (NR1H4), farnesoid X receptor/bile acid
receptor; HNF, hepatocyte nuclear factor; ICP, intrahepatic cholestasis
of pregnancy; LPS, lipopolysaccharide; MDR, multidrug resistance
gene; MRP, multidrug resistance-associated protein; NTCP (SLC10A1),
Na+/taurocholate cotransporter; OATP (SLC21A), organic anion
transporter; OST, organic solute transporter; PBC, primary biliary
cirrhosis; PFIC, progressive familial intrahepatic cholestasis; PSC,
primary sclerosing cholangitis; PXR (NR1I2), pregnane X receptor;
RARa (NR1B1), retinoic acid receptor; RXRa (NR2B1), retinoid X
receptor; SHP (NR0B2), short heterodimer partner; TNFa, tumor
necrosis factor alpha.formation depends on the proper function of distinct
membrane transport systems along the enterohepatic
route, i.e,. in hepatocytes, bile duct epithelial cells (cho-
langiocytes) and enterocytes, and its coordinated tran-
scriptional regulation by nuclear receptors (NRs) as
well as posttranscriptional mechanisms [2,3]. Hereditary
mutations of transporter genes or exposure to cholestat-
ic injury (e.g., drugs, hormones, pro-inﬂammatory cyto-
kines and biliary obstruction/destruction) result in
reduced expression and function of hepatobiliary trans-
port systems, which play an important role in the path-
ogenesis of cholestasis. In addition to genetic or
acquired transporter changes, other mechanisms such
as altered cell polarity, disruption of cell-to-cell junc-
tions and cytoskeletal changes may be involved [1].
Unravelling the molecular mechanism of cholestasis
not only extends our understanding of the pathophysio-
logical pathways but also impacts on the clinical man-
agement of patients by identifying novel targets for
diagnosis, prognosis and pharmacological interventions.
This review summarizes the principal molecular mecha-
nisms of cholestasis and their potential clinical signiﬁ-
cance with a focus on hepatobiliary transport and
metabolism of bile acids, bilirubin and other biliaryPublished by Elsevier B.V. All rights reserved.
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cholangiopathies such as primary biliary cirrhosis
(PBC) and primary sclerosing cholangitis (PSC) has
recently been summarized elsewhere [4–7].2. Principal molecular mechanisms and regulation of bile
formation
Primary secretion of bile occurs at the level of bile can-
aliculi of hepatocytes. Canalicular excretion of bile acids,
the major fraction of organic solutes in bile, is mediated
by ATP-binding cassette (ABC) transporters for bile
acids and non-bile acid organic anions and represents
the rate limiting step in bile formation [8]. Excretion of
osmotically active bile acids is followed by movement
of water via aquaporin channels and tight junctions
(‘‘bile acid-dependent bile ﬂow”). In addition to their
osmotic activity, bile acids promote canalicular secretion
of phospholipids and cholesterol for formation of mixed
biliary micelles [9]. Canalicular excretion of reduced glu-Bile Duct
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Fig. 1. Overview of hepatobiliary transporters. Hepatocellular bile acids are
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[10]. ‘‘Canalicular bile” is further modiﬁed by secretory
and absorptive processes as it passes along bile ductules
and ducts which secrete mainly bicarbonate (‘‘ductal
bile”) [4,11,12]. Several biliary compounds such as bile
acids undergo extensive enterohepatic circulation, i.e.,
are reabsorbed in the intestine, taken up again by the
liver and re-secreted into bile. Therefore, hepatocytes
excrete a mixture of primary bile acids derived from de
novo synthesis and active ileal reabsorption as well as sec-
ondary bile acids which are formed and passively reab-
sorbed in the colon after bacterial dehydroxylation
[13]. The liver expresses a range of speciﬁc uptake and
export systems for biliary compounds in hepatocytes
and cholangiocytes [2,8,14] which are summarized in
Fig. 1.
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Fig. 2. Main principles of nuclear receptor-dependent regulation of
hepatobiliary bile acid transporters and enzymes. Schematic representa-
tion of a rodent ‘‘model hepatocyte”. The principal transciptional
processes in humans are similar but less well explored. The central
regulator of bile formation is bile acid activated Fxr, either as direct
positive regulator for canalicular bile acid export via Bsep and Mrp2 as
well as phospholipid export via Mdr2 or indirectly as repressor via the
common transcriptional repressor Shp for basolateral Na+-dependent,
Ntcp and Na+-independent, Oatps, bile acid uptake as well as bile acid
synthesis via Cyp7a1. In addition, Fgf15, derived from ileal enterocytes,
also strongly represses Cyp7a1 transcription and therefore represents an
intestinal sensor for bile acid requirement. Except Osta/b which is also
regulated by Fxr, alternative export systems are independent of Fxr. Pxr
and Vdr positively regulate Mrp3, while Car positively regulates both
Mrp3 and Mrp4. Phase I (Cyp3a11 and Cyp2b10) and phase II (Sult2a1)
metabolism is stimulated by Car and Pxr, but also Fxr is able to
stimulate phase I detoxiﬁcation via Cyp3a11 and phase II glucuronida-
tion and sulfation via Ugt2b4 and Sult2a1.
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back pathways regulating bile formation under normal
and pathological conditions [8,15]. Biliary constituents
(e.g., bile acids), lipid products (e.g., oxysterols), hor-
mones and xenobiotics (e.g., drugs) activate NRs as
endogenous or exogenous ligands and thus coordinately
regulate the expression of target genes that encode hepa-
tobiliary transporters and phase I and II metabolism
enzymes [2,16–18]. The best deﬁned nuclear receptor
for bile acids, farnesoid X receptor (FXR, NR1H4), is
critically involved in the regulation of Na+-dependent
(NTCP) and Na+-independent hepatocellular bile acid
uptake (OATP1B1 and OATP1B3) [19,20], canalicular
excretion of monovalent (BSEP) [21] and divalent bile
acids (MRP2), conjugated bilirubin (MRP2) [22] and
regulates the rate limiting step of bile acid production
(CYP7A1) [23,24]. FXR either directly transactivates
expression of genes (such as BSEP, MRP2, MDR3) or
indirectly represses genes (e.g., NTCP, OATP1B1 and
CYP7A1) in a negative feedback loop via induction of
the common gene silencer small heterodimer partner
(SHP) [23–25] (Fig. 2). Collectively, activation of FXR
reduces hepatocellular bile acid concentration and bile
acid-induced toxicity and therefore represents a key
molecular target in cholestasis. The classical xenobiotic
receptors, pregnane X receptor (PXR, NR1I2), the con-
stitutive androstane receptor (CAR, NR1I3) and the
vitamin D receptor (VDR, NR1I1) are ligand-activated
NRs which also sense cholephiles (e.g., bilirubin) in
addition to bile acids. These NRs are mainly involved
in regulation of detoxiﬁcation enzymes and export
pumps for biliary compounds (for recent reviews see
[2,16,17]. The principal regulatory NR networks are
summarized in Fig. 2. To add more complexity, tran-
scriptional regulation by NRs also involves the binding
and recruitment of co-activators and co-repressors [26].
Impaired co-regulator function have been described in
metabolic diseases such as Von Gierke’s disease [27]
and play a critical role in the glucose and fatty acid
metabolism of the liver [26]. Co-regulator alterations
may also play a role in the pathogenesis of cholestasis
and could represent potential targets for future thera-
peutic interventions [28]. For the speciﬁc example of
FXR, there is a growing body of evidence that NR activ-
ity is also aﬀected by chromatin remodelling by histone
modiﬁcation through acetylation (e.g., via steroid
receptor coactivator-1, SRC-1, or p300 acetylase or
methylation (e.g., via coactivator-associated arginine
methyltransferase 1, CARM1 or protein arginine
methyltransferase1 PRMT1) [29]. In addition to
transcriptional mechanisms, post-transcriptional events
aﬀecting mRNA processing, steady-state mRNA
stability, translational eﬃcacy and/or posttranslational
changes such as transporter targeting and sorting, trans-
porter redistribution, transporter protein degradation
(e.g., via lysosomal or ubiquitin-proteasome pathway),direct protein modiﬁcations (e.g., (de-) phosphorylation,
(de-) glycosylation), changes in membrane ﬂuidity or
cis-/trans-inhibition of transport systems by cholestatic
agents (e.g., drugs) also modulate transporter expression
and function [1,3,8,30].3. Genetic defects and modiﬁer genes in cholestasis
Hereditary defects of hepatobiliary ATP-binding cas-
sette (ABC) transporters have been linked to a broad
spectrum of hepatobiliary disorders ranging from pro-
gressive familial intrahepatic cholestasis (PFIC), benign
recurrent intrahepatic cholestasis (BRIC) to intrahepatic
cholestasis of pregnancy (ICP), drug-induced cholesta-
sis, intrahepatic cholelithiasis and adult biliary cirrhosis
(Fig. 3). Homozygous high impact variants cause pro-
gressive cholestatic syndromes in neonates and children
[31,32], while lower impact variants may result in chole-
static syndromes which manifest later in juvenile or even
adult life [32,33]. Moreover, heterozygous transport
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Fig. 3. Hereditary transporter defects: a continous spectrum of liver
disease. High impact variants of homozygous transporter mutations as
tip of the pyramid can result in autosomal recessively inherited
syndromes of progressive familial intrahepatic cholestasis (PFIC)
(mutations in FIC1, BSEP or MDR3 genes) and liver involvement in
cystic ﬁbrosis (CF) (mutations in CFTR gene) in early childhood. Low
impact variants of homozygous mutations in FIC1 or BSEP and MDR3
cause benign recurrent intrahepatic cholestasis (BRIC) and low-phospho-
lipid associated cholelithiasis (LPAC) in young adults. BRIC patients
can progress to more aggressive disease indicating that PFIC and BRIC
may belong to a continuous spectrum of pathophysiologically related
conditions. Heterozygous MDR3 and – to a lesser extent – BSEP
mutations and polymorphisms may increase the susceptibility for
acquired cholestatic injury such as intrahepatic cholestasis of pregnancy
(ICP), drug induced liver injury (DILI), idiopathic adulthood ductopenia
(IAP), biliary ﬁbrosis or may play a role as modiﬁer genes in more
‘‘classic” cholangiopathies (e.g., primary biliary cirrhosis, PBC; and
primary sclerosing cholangitis, PSC). As such, a second hit/injury such as
inﬂammation, drugs or hormones may lead to decompensation and
disease development and/or determines disease progression.
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through decompensation of latent/mild defects under
challenge with drugs, hormones and/or inﬂammatory
mediators [34]. Polymorphisms in the promoter and
coding regions of transporter genes in healthy individu-
als have been associated with reduced hepatic expression
of these proteins [35–37] and, therefore, may also consti-
tute a susceptibility factor for the development of
acquired cholestasis. The role of genetic variations of
transporter expression and function for the pathogenesis
of cholangiopathies such as primary biliary cirrhosis
(PBC) and primary sclerosing cholangitits (PSC), which
constitute the major disease burden of chronic cholestat-
ic syndromes in adults, is less clear [34,38], although
recent data suggest that such polymorphisms (e.g.,
AE2, MDR3 and PXR) may determine disease progres-
sion and response to therapy.
3.1. MDR3 (ABCB4)
MDR3 is a ﬂippase, translocating phospholipids
(mainly phosphatidylcholine) from the inner to the outer
leaﬂet of the canalicular membrane for subsequent
extraction by bile acids [39]. Phospholipids in bile are
required for formation of mixed micelles (with bile acidsand cholesterol) to protect the bile duct epithelium from
the detergent properties of bile acids. Absence of biliary
phospholipids results in formation of a toxic bile dam-
aging apical membranes of cholangiocytes and hepato-
cytes [40,41]. The classic manifestation is PFIC-3
characterized by high GGT levels, bile duct disease
and progressive cholestasis in infants leading to end-
stage liver disease requiring liver transplantation in
50% of patients. MDR3 variants are also associated
with syndromatic cholesterol cholelithiasis known as
low-phospholipid-associated cholelithiasis syndrome
(LPAC) which is characterized by cholesterol gallstones
recurring after cholecystectomy, mild chronic cholestasis
due to intrahepatic stones and an increased incidence of
intrahepatic cholestasis of pregnancy (ICP) [42,43].
MDR3 mutations may also play an important role in
acquired cholestatic disorders. Several studies have iden-
tiﬁed heterozygous MDR3 mutations in patients with
ICP [40,44,45]. These patients are healthy under normal
conditions but exposure to high levels of sex hormones
in pregnancy may unmask latent/mild defects and result
in cholestasis. Patients with ICP due to MDR3 muta-
tions typically have elevated gamma-glutamyl transpep-
tidase (GGT) levels [44] although GGT levels may also
be normal [46,47]. Patients who experienced ICP may
develop subsequent chronic liver disease [40,48,49]
which so far has largely been attributed to the higher
susceptibility for biliary complications resulting from
cholesterol gallstone formation [46,50]; future studies
will have to show whether this may rather be linked to
a MDR3 cholangiopathy (see below). MDR3 gene poly-
morphisms and mutations have been associated with
drug-induced cholestasis [51]: patients with MDR3
defects may experience cholestasis when challenged with
drugs transported by MDR3 (e.g., verapamil, cyclo-
sporin A and vinblastine) thus impairing phospholipid
secretion [52].
MDR3 mutations should also be considered in adult
patients with otherwise unexplained chronic cholestasis
and biliary ﬁbrosis, since a recent study [53] has identi-
ﬁedMDR3 mutations in one-third of such patients after
exclusion of other more common causes such as PBC,
sclerosing cholangitis and granulomatous hepatitis.
The role of MDR3 in the pathogenesis of classic PBC
and PSC is still controversial. While common MDR3
polymorphisms could not be detected in Caucasian
PBC patients, a recent Japanese study reported an asso-
ciation ofMDR3 haplotypes and diplotypes with disease
progression of PBC [54–56]. These discrepancies might
in part explain regional variations in disease course
and progression but require further investigations. Since
mice lacking Mdr2 (the rodent homologue of human
MDR3) develop a cholangiopathy with macroscopic
and microscopic features of (primary) sclerosing cholan-
gitits in humans [57], a role for MDR3 defects in the
pathogenesis of large bile duct diseases (including
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tions have not be associated with pathogenesis of PSC
[54,58], which indeed would have been quite unexpected
regarding the complex pathophysiology of this disease.
However, variations in the MDR3 gene may inﬂuence
disease progression in PSC patients and also disease sus-
ceptibility in interaction with other transporter gene
polymorphisms as demonstrated for the organic solute
transporter (OSTa) gene [59]. MDR3 variants could be
more relevant in speciﬁc subphenotypes of PSC (e.g.,
pediatric PSC, female patients with gallstones) [60].
Moreover, MDR3 defects have been linked to non-
anastomotic intrahepatic bile duct strictures (NAS) after
liver transplantation.Bile cytotoxicity, in particular a
low biliary phospholipids/bile salt ratio may be involved
in the pathogenesis of NAS [61], since biliary bile acid
excretion recovers more rapidly than phospholipid
excretion after liver transplantation, leading to a more
hydrophobic biliary bile acid composition [62]. These
data suggest that the impact of cold ischemia/reperfu-
sion injury on MDR3 expression and function – in par-
ticular in genetically susceptible individuals with an
MDR3 genetic variation could contribute to NAS. This
hypothesis is further supported by ﬁndings in heterozy-
gous Mdr2+/ mice, which secrete only 50% of the nor-
mal amount of phosphatidylcholine into bile and
developed bile duct injury and cholestasis after liver
transplantation in contrast to their wild-type littermates
[63].
3.2. BSEP (ABCB11)
BSEP is the main canalicular bile salt export pump
for monovalent bile acids such as glycine- or taurine-
amidates of cholic acid (CA), chenodeoxycholic acid
(CDCA) and ursodeoxycholic acid (UDCA) [8]. BSEP
is the driving force of bile salt-dependent bile ﬂow and
impaired expression and/or function of BSEP causes sig-
niﬁcant cholestasis. Mutations in the BSEP gene result
in PFIC-2 [64]. In contrast to PFIC-3, liver damage in
PFIC-2 is restricted to hepatocytes since bile acids do
not reach bile canaliculi and bile ducts explaining nor-
mal GGT levels in these patients. Accumulation of bile
acids in hepatocytes causes giant cell hepatitis and pro-
gressive liver damage disease requiring liver transplanta-
tion at early age [32]. Some children may also develop
hepatocellular carcinoma, which might be linked to the
mutagenic potential of bile acids [65,66]. A milder vari-
ant of PFIC-2 is benign intrahepatic recurrent cholesta-
sis (BRIC-2), which is also associated with a high risk
for the development of gallstones [67]. The distinction
between progressive and benign forms of cholestasis in
the present nomenclature suggests that these are entirely
separate syndromes. However, recent data indicate that
many of the so-called BRIC patients can progress to
more aggressive disease over time, indicating that PFICand BRIC rather belong to a continuous spectrum of
pathophysiologically related conditions.
Similar to MDR3, BSEP variants may also play a
role in the pathogenesis of ICP [44,68]. Heterozygosity
for the common BSEP mutations accounts for about
1% of European ICP cases [69]. A polymorphism lead-
ing to an exchange of valine to alanine at position 444
of the BSEP protein (V444A) is a signiﬁcant risk factor
for ICP [68,69]. Interestingly, ICP was associated with
heterozygosity for the V444A polymorphism, while all
patients with contraceptive-induced cholestasis were
homozygous for this polymorphism [68]. This indicates
that lower estrogen levels in contraceptive-induced cho-
lestasis compared to second or third trimester pregnancy
require two low-function alleles to result in cholestasis
[68]. Since sulphated progesterone metabolites are
increased in ICP [70], inhibition of BSEP function
through such metabolites might also contribute to ICP
[71]. In contrast to MDR3-associated ICP, BSEP poly-
morphisms in ICP do not lead to elevation of GGT lev-
els [68] which may help to phenotypically distinguish
MDR3 and BSEP-related forms of ICP (similar to
PFIC). The diﬀerentiation could be of clinical relevance,
since patients with MDR3 mutations may later develop
chronic liver disease [40,48,49]. Combined homozygous
mutations of both BSEP and MDR3 have been
described in one ICP patient causing even more severe
cholestasis [72].
BSEP mutations have also been linked to drug-
induced liver injury [51]. The V444A polymorphism
has been associated with a threefold increased risk to
develop cholestatic drug side eﬀects in response to treat-
ment with diﬀerent drugs (i.e., beta-lactam antibiotics,
proton pump inhibitors, oral contraceptives and psycho-
tropic drugs) [51]. A functional explanation for the
increased risk of cholestasis may lie in decreased BSEP
expression levels in patients carrying this polymorphism
[73]. So far, no strong role of BSEP genetic variants for
the pathogenesis of cholangiopathies such as PBC and
PSC could be established [54,55].
3.3. FIC1 (ATB8B1)
FIC1 is considered to be an inward ﬂippase for phos-
phatidylserine which may be crucial for maintaining cell
membrane asymmetry [74,75]. FIC1 is expressed
broadly in tissues throughout the body including the uri-
nary bladder, intestine, pancreas and stomach and hepa-
tocytes, where it is localized to the canalicular
membrane. FIC1 deﬁciency causes severe cholestatic
liver disease indicating an important function in bile
secretion. Mutations in the FIC1 gene cause PFIC-1
[76], also known as Byler disease, presenting in the neo-
natal period and characterized by elevated levels of
serum bile acids, bilirubin and transaminases, low bili-
ary bile acid concentrations and low levels of GGT.
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requiring liver transplantation at early age. Consistent
with the wide extrahepatic expression of FIC1, liver
transplantation only resolves cholestasis, but not the
extrahepatic manifestations such as diarrhea, bile acid
malabsorption, pancreatitis and nephrolithiasis [77].
The exact pathomechanism by which FIC1 deﬁciency
leads to cholestasis is still under investigation. FIC1 deﬁ-
ciency is associated with reduced FXR expression and
function which may result in disturbance of intestinal
and hepatic bile acid transporter expression [78–80].
This hypothesis was further strengthened in an in vitro
model where FIC1 overexpression led to enhanced phos-
phorylation and nuclear localization of FXR associated
with activation of its target gene BSEP. In line with this
hypothesis, Byler disease FIC1 mutants did not activate
BSEP, and BRIC mutants only partially activated BSEP
expression [80]. This contrasts the ﬁndings of a recent
study, where FXR activity remained after FIC1
knock-down [81]. Another possible explanation for cho-
lestasis in FIC1 deﬁciency leading to decreased or even
absent ﬂippase activity is the loss of phospholipid asym-
metry of the canalicular membrane. This in turn destabi-
lizes the canalicular membrane rendering it less resistant
towards hydrophobic bile acids [74,81]. Furthermore,
the loss in phospholipid asymmetry may reduce bile acid
transport via reduced BSEP activity thus contributing to
cholestasis [74,81].
A milder form of PFIC-1 also caused by phenotypi-
cally less severe mutations in the FIC1 gene is BRIC-1
(Summerskill syndrome). BRIC-1 is characterized by
recurrent episodes of cholestasis not necessarily leading
to liver cirrhosis [76], although recent reports suggest
that BRIC-1 may also progress to a form that is indistin-
guishable from PFIC-1 [82]. One might speculate that in
BRIC-1 patients residual activity of FIC1 may still be
present, while in PFIC-1 patients this activity is com-
pletely lost [32]. Consistent with this concept, BRIC-1
and PFIC-1 may be considered the far ends of a contin-
uous disease spectrum. Similar to MDR3 and BSEP,
mutations in the FIC1 gene have also been linked to
ICP [83,84]. Whether FIC1 polymorphisms or mutations
are associated with other cholestatic liver diseases
remains to be determined.
3.4. MRP2 (ABCC2)
MRP2 mediates canalicular excretion of conjugated
bilirubin and a broad range of organic anions (e.g.,
conjugates with glutathione, glucuronate and sulfate
formed by phase II conjugation). MRP2-dependent
excretion of reduced glutathione (GSH) critically
determines bile acid-independent bile ﬂow [85]. In
addition, MRP2 transports divalent bile acids with
two negative charges such as sulfated tauro- or
glycolithocholate.Mutations in the MRP2 gene are found in patients
with Dubin–Johnson syndrome resulting in jaundice
while typical features of cholestasis such as elevated
serum bile acid levels and pruritus are absent [86]. The
only acquired cholestatic liver disease associated with
MRP2 mutations identiﬁed so far, is ICP [87]. Second-
ary alterations of this transporter (repression of tran-
scription, posttranslational changes or direct inhibition
of MRP2 function; see below) may play a more impor-
tant role in the pathogenesis of cholestasis than heredi-
tary defects.
3.5. AE2 (SLC4A2)
Anion exchanger AE2 mediates Cl/HCO3 exchange
thus regulating intracellular pH and biliary HCO3 excre-
tion by hepatocytes and cholangiocytes. Expression of
AE2 is reduced in patients with PBC and may contribute
to reduced bile ﬂow and cholestasis [88–90]. Moreover,
AE2 expression is also reduced in salivary and lacrimal
glands of PBC patients thus contributing to Sjo¨gren’s
syndrome, which is frequently associated with PBC.
Ursodeoxycholic acid (UDCA) treatment improves
AE2 expression [89] and function [90]. UDCA and glu-
cocorticoids synergistically stimulate AE2 promoter
activity via interactions with hepatocyte nuclear factor
1 (HNF1) and the glucocorticoid receptor (GR,
NR3C1). Conversely, progression of PBC despite
UDCA therapy has been linked to allelic variations in
the AE2 gene [55]. The molecular link between AE2
and PBC is further supported by the ﬁndings in Ae2
knockout mice [91] which develop biochemical, serolog-
ical, immunological and histopathological features of
PBC including development of animitochondrial anti-
bodies. Ae2 deﬁciency not only leads to disturbances
in intracellular pH homeostasis in cholangiocytes but
also in immunocytes which may explain the immunolog-
ical and functional changes seen in PBC patients [91,92].
3.6. CFTR (ABCC7)
The cystic ﬁbrosis transmembrane regulator (CFTR)
is a cAMP-dependent chloride channel. Mutations in
the CFTR gene cause cystic ﬁbrosis [93]. Impaired bicar-
bonate and ﬂuid secretion in CF may result in inspis-
sated bile, which can be toxic to the bile duct
epithelium. Hepatobiliary complications from CF occur
in up to 25% of patients ranging from prolonged neona-
tal cholestasis, hepatic steatosis and focal nodular cir-
rhosis to multilobular cirrhosis and biliary tract
complications such as stones and sclerosing cholangitis.
Four percentage to 18% of adult CF patients show chol-
angiographic features of sclerosing cholangitis, some-
times even in association with inﬂammatory bowel
disease [94]. Vice versa, induction of colitis in Cftr
knockout mice causes bile duct injury [95] making
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ingly, an increased prevalence of CFTR variants was
observed in a subset of PSC patients with inﬂammatory
bowel disease [96]. The identiﬁed CFTR mutations were
also associated with a reduced chloride secretory
response [96]. Another study observed a high prevalence
of CFTR mutations and decreased CFTR function in
childhood PSC [97]. However, several other studies
could not conﬁrm an association of disease-causing
CFTR mutations with PSC [98,99] and a recent study
by Henckaerts et al. even identiﬁed speciﬁc dysfunc-
tional CFTR-variants that might protect against the
development of PSC [99]. Thus, the underlying mecha-
nisms still remain elusive and whether CFTR is indeed
a modiﬁer gene for development of PSC needs to be
determined in larger numbers of patients.
3.7. Other genetic variants associated with cholestasis
In addition to genetic defects in transporter genes,
variations in tight junction genes can also cause chole-
stasis. Missense mutations in tight junction protein 2
have been identiﬁed in patients with familial hypercho-
lanemia, an oligogenic disease requiring a functional
alteration in a second gene (i.e., bile acid amino acid
transferase) for full phenotypic manifestation [100]. Fur-
thermore, mutations of claudin-1, which forms the back-
bone of tight junctions with occludin and junctional
adhesion molecules causes neonatal sclerosing cholangi-
tis associated with ichthyosis [101]. Mutations in JAG-1,
which is involved in notch signalling required for bile
duct development, have been identiﬁed in patients with
Alagille syndrome, an autosomal dominant disorder,
which results in cholestasis due to bile duct paucity
[102]. Inborn errors of bile acid synthesis are well estab-
lished causes of neonatal cholestasis (for review see
[103]). Genetic defects in nuclear receptors regulating
gene expression of hepatobiliary transporters and
enzymes may also be involved in cholestatic liver disease
or potential response to therapy. The nuclear receptor
FXR has been linked to ICP [104] and gallstone disease
[105]. In addition, functional PXR gene variants appear
to modify disease course in PSC and weakly in PBC
[55,106].4. Acquired defects and adaptation to cholestasis
In general, the acquired changes in transporter
expression in human cholestatic liver diseases (alcoholic
hepatitis, PBC, PSC, malignant obstruction) are consis-
tent with concepts derived from the ﬁndings in experi-
mental animal models of cholestasis [2,17,107]. These
models include common bile duct ligation (CBDL,
model for biliary duct obstruction), endotoxin challenge
(sepsis/inﬂammation-induced cholestasis) or administra-tion of ethinylestradiol (cholestasis of pregnancy) [108]
and have permited important mechanistic insights into
cholestasis. Bile acid feeding is commonly used to inves-
tigate direct eﬀects of bile acids without (peri-)operative
stress or induction of pro-inﬂammatory cytokines as
observed during CBDL [109].
While some of the acquired (e.g., cytokine-mediated)
alterations contribute to cholestasis [2], other (e.g., bile
acid-induced) changes may represent compensatory
(‘anti-cholestatic’) defense mechanisms which provide
alternative excretory routes for accumulating chole-
philes in cholestasis. Rising intrahepatic and systemic
bile acid levels under cholestatic conditions orchestrate
an adaptive response, which is mainly coordinated by
a complex interplay of bile acid and bilirubin-activated
nuclear receptors (mainly FXR, PXR and CAR), in an
attempt to counteract cholestatic liver injury. As a result
of this transcriptional program, basolateral bile acid
uptake systems are markedly reduced (e.g., NTCP,
OATPs), while basolateral bile acid export pumps are
increased simultaneously (e.g., MRP3, MRP4 and
OSTa/b), which is considered to be a major hepatocellu-
lar defense mechanism counteracting intracellular bile
acid toxicity [16,17,108] (Fig. 4). In addition, bile acid
hydroxylation and conjugation via phase I and phase
II enzyme reactions reduces toxicity and increases water
solubility for subsequent alternative elimination of
cholephiles via the urine [3,16,108,110]. These adaptive
modulations in response to cholestasis are not only
restricted to the liver but also occur in intestine, kidney
and bile duct epithelia [16,17,108] (Fig. 4). Intestinal and
renal bile acid uptake and export transporter systems
can adapt to local bile acid concentrations and thus
are able to increase fecal and/or urinary bile acid elimi-
nation. In obstructed bile ducts, bile acid reuptake and
delivery to the liver for subsequent detoxiﬁcation is
increased [16,17,108]. Unfortunately this armamentar-
ium of adaptive responses is apparently too weak to
fully prevent cholestatic injury. Part of this may be
due to the fact, that cholestatic/inﬂammatory injury
results in repression of nuclear receptor expression and
function [111–113]. However, these responses might be
targeted/enhanced therapeutically by nuclear receptor
activating drugs.
4.1. Obstructive cholestasis
Biliary obstruction in rodents initiates marked
changes in transporter expression. As an important pro-
tective regulatory step, the basolateral Na+-dependent
bile acid uptake system, Ntcp, which extracts the great
bulk of bile acids returning to the liver is downregulated
to prevent bile acid uptake into hepatocytes [114]. Accu-
mulation of bile acids activates Fxr and subsequently
induces Shp resulting in repression of Ntcp [25,115]
(Fig. 2). The importance of this mechanism is underlined
Fig. 4. Overview of adaptive response in cholestasis. Cholestasis results in intrahepatic accumulation of bile acids. To limit toxic hepatocellular bile acid
burden further uptake of bile acids is restricted by downregulation of NTCP and OATPs. Intrahepatic de-novo synthesis of bile acids is downregulated via
CYP7A1, mediating the rate limiting step in bile acid biosynthesis. Moreover, intrahepatic bile acids can be detoxiﬁed via phase I hydroxylation and
phase II conjugation reactions mediated via cytochrome p450 enzymes, glucuronidases and sulfatases. These modiﬁcations render intrahepatic bile acids
more hydrophilic and facilitate their elimination. Export of bile acids in cholestasis is enhanced by upregulation of basolateral adaptive overﬂow
transporters, such as MRP3, MRP4 and OSTa/b, which are normally expressed only at low levels under physiological conditions. Hydrophilic bile acids
can then be eliminated via the kidney either via glomerular ﬁltration or potentially also via additional active ATP-transporter mediated tubular secretion.
In addition, reduced intestinal bile acid uptake via reduced expression of ASBT contributes to reduced systemic bile acid accumulation via enhancing fecal
excretion of bile acids (not shown).
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CBDL [116]. In contrast, CBDL in Shp knockout mice
results in downregulation of Ntcp, suggesting that
Shp-independent mechanisms might also be involved
[117]. Such mechanisms may involve bile acid-dependent
suppression of the Hnf4a/Hnf1a pathway as a key path-
way of Ntcp gene regulation [2,118]. In contrast to bile
acid uptake, expression of the major canalicular bile
acid exporter Bsep, is largely maintained during biliary
obstruction and may limit the extent of liver injury
resulting from bile acid retention particularly when cho-
lestasis is prolonged [119]. However, enhancing bile ﬂow
in the presence of complete biliary obstruction may
aggravate cholestatic liver injury through development
of bile infarcts [57]. Indeed, Fxr knockout animals,
which have lower bile ﬂow and biliary pressure, develop
fewer bile infarcts as typical lesion in obstructive chole-
stasis [120]. These results may imply some precautions
for the potential use of bile ﬂow stimulating drugs in
cholestatic liver disease, especially those with a signiﬁ-
cant obstructive component (e.g., PSC) [120,121].
The mechanism of alternative basolateral Mrp3 and
Mrp4 induction in obstructive cholestasis has not yet
been fully elucidated. NRs such as Pxr and Car, which
can be activated by accumulated cholephiles such as bileacids ore bilirubin, or NF-E2-related factor (Nrf2),
which is a common regulator of basolateral Mrp expres-
sion may be involved [122,123] (Fig. 2). Pxr and Car
agonists induce these basolateral overﬂow system
Mrp3 and Mrp4 together with phase I and phase II
detoxiﬁcation enzymes, thereby lowering biochemical
markers of cholestasis [124]. These eﬀects are not seen
in the respective knockout animals under cholestatic
conditions [121]. However, the overall importance of
single basolateral transporters as adaptive overﬂow sys-
tems should not be overestimated, since Mrp3 and Mrp4
knockout animals do not show an overtly aggravated
cholestatic phenotype in CBDL [125,126] and so far
no signiﬁcant human mutations or polymorphisms in
MRP3 and MRP4 have been reported. The importance
of upregulation of heteromeric OST/Osta/b [127], which
is a FXR/Fxr dependent basolateral bile acid overﬂow
system, for obstructive cholestasis still needs to be deter-
mined, but underlines again the central role of FXR/Fxr
in regulating bile acid shuttling in and out of hepato-
cytes (Fig. 2).
Cyp7a1, the rate limiting enzyme in bile acid biosyn-
thesis is paradoxically induced in obstructive cholestasis
and may further contribute to bile acid accumulation via
continuous endogenous bile acid production [128,129].
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cascade critically regulates the demand of bile acids
from an ‘‘intestinal perspective” [130]. Fibroblast
growth factor 15 (Fgf15), a hormone-like factor, is
induced by bile acid binding to Fxr in the terminal ileum
and signals from the gut to the liver, where it represses
bile acid biosynthesis in concert with Shp via downreg-
ulation of Cyp7a1 [131] (Fig. 2). In obstructive cholesta-
sis, when enterocytes face only small amounts of bile
acids, ileal Fgf15 is low and hepatic Cyp7a1 levels inap-
propriate high [131]. Therapeutic activation of ileal Fxr
is therefore thought to reduce bile acid burden under
obstructive cholestatic conditions and might signiﬁ-
cantly contributed to the beneﬁcial eﬀects of GW4064,
an Fxr agonists with a poor absorptive rate, in CBDL
rats [132] (Fig. 4). The role of human FGF19 signalling
(the human ortholog of murine Fgf15) in human
obstructive cholestasis and its potential eﬀects on bile
acid synthesis is, however, less clear and still needs to
be deﬁned [133,134].
In human cholestatic liver disease, most changes in
hepatobiliary transporters and enzymes may be inter-
preted as a consequence of elevated bile acid levels
and represent adaptive mechanisms similiar to cholestat-
ic animal models. In early stage PBC and PSC, when bil-
irubin and bile acid levels are still within the normal
range, hepatobiliary transporter expression is not chan-
ged. Late stage cholangiopathies or malignant extrahe-
patic cholestasis, however, results in repression of
basolateral uptake systems and induction of basolateral
overﬂow pumps such as MRP3, MRP4 and OSTa/b
[111,135,136].
The reduction of intestinal bile acids in obstruc-
tive cholestasis results in disruption of intestinal bar-
rier integrity and mucosal defense leading to
endotoxemia and potential worsening and perpetua-
tion of the cholestatic condition. Bile acids inhibit
bacterial growth in vitro and bacterial overgrowth
and translocation in vivo [137,138]. Conversely,
absence of bile leads to bacterial overgrowth, muco-
sal injury, bacterial translocation and endotoxinemia
in the small intestine [138,139]. Again, the bile acid
receptor Fxr, has been linked as a central integrator
to intestinal mucosal defense [139]. Fxr agonists are
able to block bacterial overgrowth, translocation,
mucosal injury and neutrophil extravasation in com-
mon bile duct ligated mice, while Fxr knockout mice
have higher intestinal bacterial counts, higher rates
of bacterial translocation and mucosal injury [139].
Thus, a picture is emerging where under physiologi-
cal conditions bile acids inhibit bacterial overgrowth
in the proximal small intestine directly and in the
distal small intestine indirectly by their signalling
properties via Fxr. Again, this concept would favour
therapeutic FXR activation in the gut in cholestatic
conditions.4.2. Inﬂammation-induced cholestasis
Cholestasis frequently occurs as a complication in
patients with sepsis, extrahepatic bacterial infections
and alcoholic hepatitis [140,141]. Endotoxin (lipopoly-
saccharide, LPS) and LPS-induced pro-inﬂammatory
cytokines such as tumor necrosis factor (TNF) a, inter-
leukin-1 (IL-1) b and interleukin-6 (IL-6) are secreted
mainly by macrophages and Kupﬀer cells [142,143],
but hepatocytes per se can be a source of proinﬂamma-
tory cytokines [144]. Pro-inﬂammatory cytokines are
potent inhibitors of hepatobiliary transport and NR
expression and function [2,145,146]. The transport of
organic anions at both the sinusoidal and canalicular
membrane of hepatocytes is reduced and both bile
acid-dependent and bile acid-independent fractions of
bile ﬂow are aﬀected [147,148].
LPS leads to a rapid and marked down-regulation of
Ntcp [149,150] via decreased binding activity of the
nuclear transcription factors Hnf1a and Rxra:Rara to
the (rat) Ntcp gene promoter In contrast to CBDL,
LPS-induced cytokines reduce Ntcp expression without
induction of Shp [116,151]. Reduced canalicular secre-
tion of bile acids and other organic anions during endo-
toxemia is caused by a concomitant reduction of the
canalicular export pumps Bsep and Mrp2 [119,152].
Transcriptional control of Bsep and Mrp2 is mediated
by a group of nuclear hormone receptors including
Fxr, Rar, Pxr and Car (Fig. 2) [21,22,153,154]. Phos-
phorylation and nuclear export of the common NR het-
erodimer partner Rxra represents one component of the
uniformly decreased transporter gene expression during
LPS-induced cholestasis [155,156]. Furthermore, LPS-
induced down-regulation of Bsep mRNA may be medi-
ated by suppression of Fxr [21,157]. In addition,
decreased activity of Pxr and Car may be important
forMrp2 repression [112,157,158] (Fig. 2). In the regula-
tion of the human transporter genes under inﬂammatory
conditions posttranscriptional mechanisms play a more
prominent role. In LPS-treated human liver slices BSEP
and MRP2 mRNA levels are unaltered whereas both
proteins are virtually absent under these conditions
[159]. Similarly, reductions in canalicular BSEP and
MRP2 staining have been observed in liver biopsies
from patients with inﬂammation-induced cholestasis
[160]. Transporter retrieval from the canalicular mem-
brane has been described as a potential posttranscrip-
tional mechanism of early and reversible regulation of
Mrp2 during endotoxemia [161]. In contrast to canalic-
ular transporter regulation, much less is known about
the regulation of the basolateral overﬂow systems dur-
ing inﬂammatory cholestasis (for review [162]).
The understanding of inﬂammation-induced chole-
stasis is further expanded by ﬁndings demonstrating
interaction of nuclear receptors with the inﬂammatory
response cascade. Inﬂammation-induced activation of
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tional regulator of classical pro-inﬂammatory target
genes such as TNFa, antagonizes Fxr activity and Fxr
target gene expression and livers from Fxr knockout
mice are more susceptible to inﬂammatory (e.g.,
LPS-induced) stress than wildtype animals [145]. Recip-
rocally, Fxr activation inhibits hepatocellular NF-jB
activation [145]. In cells which do not express FXR/
Fxr (e.g., Kupﬀer cells/macrophages) anti-inﬂammatory
and immunosuppressive properties of bile acids may be
mediated via the membrane-bound G-protein-coupled
bile acid receptor TGR5/Tgr5 [163,164].
4.3. Drug-induced cholestasis, steroid-induced cholestasis
Drugs can cause cholestasis by inhibiting hepatocel-
lular transporter expression and function and, in rare
cases, by inducing a vanishing bile duct syndrome,
which can progress to biliary cirrhosis [36]. Many cases
of drug-induced cholestasis result from a functional
inhibition of transport proteins by the drug itself or its
metabolites. Drugs can directly cis-inhibit ATP-depen-
dent bile acid export via Bsep in a competitive manner
(e.g., cyclosporine, rifampin, bosentan, troglitazone
and glibenclamide) [165–167]. In addition, steroid hor-
mones such as estrogen and progesterone metabolites
are able to indirectly trans-inhibit Bsep function after
their secretion into bile via Mrp2 [165]. Inhibition of
MRP2 by drugs, such as the antibiotic fusidate, may
also contribute to cholestasis and jaundice [168].
Phospholipid secretion via MDR3 might be impaired
by verapamil, cyclosporin A, and vinblastine, since these
compounds are transported by MDR3 in vitro [52]. Last
but not least, genetic variations in transporter genes can
predispose to drug- and steroid-induced cholestasis (see
above). The detailed molecular mechanisms of drug-
and steroid induced cholestasis have recently been
reviewed elsewhere [169]. However, it has to be kept in
mind that many adverse hepatic drug reactions are
accompanied by an inﬂammatory element, and therefore
may more resemble the features of inﬂammation-associ-
ated cholestasis.5. Therapeutic strategies and outlook
So far, the only approved drug for treatment of
cholestatic disorders is ursodeoxycholic acid (UDCA),
which is a hydrophilic bile acid and normally accounts
for only small parts of the human bile acid pool [110].
Proposed anti-cholestatic mechanisms of UDCA action
include stimulation of canalicular eﬄux pumps (i.e.,
MRP2, BSEP) at a transcriptional and posttrancription-
al level for ‘‘orthograde” biliary excretion and stimula-
tion of basolateral export pumps (i.e., MRP3, MRP4)
for adaptive alternative excretion of bile acids back fromhepatocytes into the systemic circulation [111,170–173].
In addition, UDCA may also have antiapoptotic and
antiﬁbrotic properties contributing at least to some of
the beneﬁcial eﬀects [110]. However, in prototypic chole-
static liver diseases such as PBC, up to one to two third
of patients only incompletely respond to UDCA and
remain at continued increased risk for disease progres-
sion to cirrhosis and potential need for liver transplanta-
tion [174,175]. UDCA has no proven beneﬁt in PSC
[176–178]. Therefore, additional therapeutic strategies
for chronic cholangiopathies such as PBC and PSC are
required.
Currently, a promising novel treatment option for
cholestasis are FXR agonists (e.g., 6-ethylchenodeoxy-
cholic acid) and phase II studies have already been initi-
ated for PBC. At least in rats, FXR/Fxr agonists were
shown to improve intrahepatic and extrahepatic chole-
stasis [132]. Therapeutic FXR ligands could overcome
the reduction of bile ﬂow in cholestasis via stimulation
of BSEP (increasing bile acid-dependent bile ﬂow) and
MRP2 (increasing bile acid-independent bile ﬂow)
[22,179]. FXR agonists may also support some adaptive
reactions of the cholestatic hepatocyte to limit the hepa-
tocellular bile acid burden, such as down-regulation of
bile acid import and induction of basolateral overﬂow
systems as well as repression of endogenous bile acid
synthesis [2,16,108]. In addition, stimulation of the can-
alicular phospholipid ﬂippase MDR3 via FXR is pre-
dicted to render bile composition less aggressive
[180,181].
NorUDCA, is a side chain shortened UDCA derivate
and promising candidate for sclerosing cholangitis [182].
Its relative resistance to amidation results in enhanced
cholehepatic shunting from the bile duct lumen back
to the hepatocytes, thereby inducing a bicarbonate rich
and potentially less toxic bile ﬂow [183]. In addition,
norUDCA is enriched in the hepatocytes by this mecha-
nism and markedly induces phase I and phase II detox-
iﬁcation enzymes and alternative basolateral overﬂow
systems via yet unidentﬁed transcriptional mechanisms
[182]. Similar to UDCA, no deﬁnite nuclear receptor
for the action of norUDCA has been deﬁned. In contrast
to UDCA, norUDCA heals sclerosing cholangitis in a
mouse model resembling PSC [182]. The beneﬁcial
impact of norUDCA on bile acid metabolism and
transport are accompanied by anti-ﬁbrotic and
anti-inﬂammatory eﬀects [182]. Since stimulation of
bicarbonate-rich choleresis by norUDCA is mostly
independent from Cftr in mice, this drug may also be
an interesting treatment option for CFTR-associated
cholangiopathies [184].
A range of additional nuclear (e.g., PXR, CAR and
PPARa) and bile acid (e.g., TGR5) receptor agonists,
which impact on detoxiﬁcation and alternative export
mechanisms, bile composition, ﬁbrosis and inﬂamma-
tory responses are currently under investigation with
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drugs such as rifampicin and phenobarbital have been
used in the pre-UDCA area for the treatment of chole-
static pruritus and jaundice and later turned out to be
activators of PXR and CAR, respectively [185,186]. Also
agonists of peroxisome proliferator-activated receptor
alpha (PPARa, NR1C1) are promising therapeutic
approaches in human cholestatic liver disease since
ﬁbrates showed beneﬁcial eﬀects on biochemical param-
eters of cholestasis and/or transaminases in PBC patients
with suboptimal response to UDCA [187–189]. A pro-
posed mode of action could be stimulation of MDR3/
Mdr2 by PPARa agonists [190,191]. The future could
bring us ‘cocktails’ of gene-selective agonists in order
to speciﬁcally target subsets of genes and separate
desired from unwanted eﬀects. Another future level of
intervention could be co-activators/co-repressors and
histone modifying enzymes whose expression may also
be altered in cholestatic and metabolic liver diseases [26].
In summary, the molecular mechanisms leading to
cholestasis and protecting from cholestasis are complex.
While some of these hereditary or acquired changes
result in reduced transporter function and cholestasis,
most of the observed changes are consequences rather
than cause of cholestasis. Both primary and secondary
alterations and their underlying regulatory mechanism
are worthwhile pharmacological targets for the future
treatment of cholestasis.
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